Impact of HIV type 1 subtype variation on viral RNA quantitation

AIDS Research and Human Retroviruses

Volumn 15, Issue 2, 1999, Pages 133-142

  Parekh, Bharat ^a,c   Phillips, S ^a   Granade, T C ^a   Baggs, J ^b   Hu, Dale J ^b   Respess, R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA B; VIRUS RNA;

ARTICLE; ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0033585484     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311556     Document Type: Article

References (41)

1. Hogervorst E, Jurriaans S, Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, Gemen B, Coutinho R, Miedema F, and Goudsmit J: Predictors of non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3 specific antibody levels. J Infect Dis 1995;171: 811-821.
2. Iuliano R, Forastieri G, Brizzi M, Mecocci L, Mazzotta F, and Ceccherini-Nelli L: Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline. J Acquir Immune Defic Syndr Hum Retroviral 1997;14:408-414.
3. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, and Rinaldo CR Jr: Plasma viral load and CD+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126: 946-954.
4. Michael NL, Chang G, Kim JH, and Birx DL: Dynamics of cell-free viral burden in HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retroviral 1997;14:237-242.
5. Balotta C, Colomba MC, Colucci G, Vigano A, Riva C, Papagno L, Violin M, Crupi L, Bricalli D, Salvaggio A, Moroni M, Principi N, and Galli M: Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1997; 16:205-211.
6. Bruisten SM, Frissen PH, Van Swieten P, Harrigan PR, Kinghorn I, Larder B, Weigel HM, De Vries E, Regez RM, Henrichs JH, Koot M, and Huisman JG: Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons. AIDS Res Hum Retroviruses 1997; 13:327-335.
7. Cao Y, Qin L, Zhang L, Safrit J, and Ho DD: Characterization of long-term survivors of human immunodeficiency virus type 1 infection. Immunol Lett 1996;51:7-13.
8. Katzenstein TL, Pederson C, Neilson C, Lundgren JD, Jakobsen PH, and Gerstoft J: Longitudinal serum HIV RNA quantification: Correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996;10:167-173.
9. Lambert G, Thea DM, Pliner V, Steketee RW, Abrams EJ, Matheson P, Thomas PA, Greenberg B, Brown TM, Bamji M, Kalish ML, and the New York City Perinatal HIV Transmission Collaborative Study Group: Effect of maternal CD4+ cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr 1997;130:890-897.
10. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
11. Operskalski EA, Mosley JW, Busch MP, and Stream DO: The influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:243-244.
12. Salvatori F, Maserio S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, and De Rossi A: Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease. J Virol 1997;71:4694-4706.
13. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA, and the Women and Infants Transmission Study Group: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-1342.
14. Vesanen M, Stevens CE, Taylor PE, Rubinstein P, and Saksela K: Stability in controlling viral replication identifies long-term non-progressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J Virol 1996;70:9035-9040.
15. Zaknun D, Orav J, Kornegay J, al-Attar I, Fuchs D, Zaknum J, Wachter H, Chatis P, Burchett SK, and McIntosh K: Correlation of ribonucleic acid polymerase chain reaction, acid dissociated p24 antigen, and neopterin with progression of disease. A retrospective, longitudinal study of vertically acquired human immunodeficiency virus type 1 infection in children. J Pediatr 1997;130:898-905.
16. Aleixo LF, Goodenow MM, and Sleasman JW; Zidovudine administered to women infected with human immunodeficiency virus type 1 and to their neonates reduces pediatric infection independent of an effect on levels of maternal virus. J Pediatr 1997;130: 906-914.
17. Cao Y, Krogstad P, Korber BT, Houp RA, Muldoon M, Macken C, Song JL, Jin Z, Zhao JO, Clapp S, Chen IS, Ho DD, and Ammann AJ: Maternal HIV-1 viral load and vertical transmission of infection: The Ariel project for the prevention of HIV transmission from mother to infant. Nature Med 1997;3:549-552.
18. Coll O, Hernandez M, Boucher CA, Fortuny C, de Tejana BM, Canet Y, Caragol I, Tijnagel J, Bertran JM, and Espanol T: Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: 26-30.
19. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm ER, and Bryson YJ: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1997;275:599-605.
20. Fiore JR, Zhang YJ, Bjorndal A, Di Stefano A, Angarano G, Pastore G, and Fenyö EM: Biological correlates of HIV-1 heterosexual transmission. AIDS 1997;11:1089-1094.
21. Gupta P, Mellors J, Kingsley L, Riddler S, Singh MK, Schreiber S, Cronin M, and Rinaldo CR: High viral load in semen of human immunodeficiency virus type 1 infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997;71:6271-6275.
22. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, and Sullivan JL: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-1629.
23. Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, Matheson PB, Abarms EJ, Bamji M, Lambert G, Schoenbaum EA, Thomas PA, Heagarty M, and Kalish ML: The effect of maternal viral load on the risk of prenatal transmission of HIV-1. AIDS 1997;11:437-444.
24. Dyers JR, Gilliam BL, Eron JJ, Grosso L, Cohen MS, and Fiscus SA: Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: Comparison of NASBA with Amplicor reverse-transcription-PCR amplification and correlation with quantitative culture. J Virol Methods 1997;60:161-170.
25. Vandamme AM, Schmit JC, Van Dooren S, Van Laethem K, Gobbers E, Kok W, Goubau P, Witvrouw M, Peetermans W, De Clercq E, and Desmyter J: Quantification of HIV-1 RNA in plasma: Comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test. J Acquir Immune Defic Syndr Hum Retrovirol 1997;13:127-139.
26. Gobbers E, Fransen K, Oosterlaken T, Janssens W, Heyndrickx, L, Ivens T, Vereecken K, Schoones R, van de Wiel P, and van der Groen G: Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regards to different HIV-1 subtypes. J Virol Methods 1997;66:293-301.
27. Alaeus A, Lidman K, Sonnerborg A, and Albert J: Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 1997;11:859-865.
28. Wilber JC: Branched DNA for quantification of viral load. Immunol Invest 1997;26:9-13.
29. Coste J, Montes B, Reynes J, Peeters M, Segarra C, Vendrell J-P, Delaporte E, and Segondy M: Comparative evaluation of three assays for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol 1996;50:293-302.
30. Coste J, Montes B, Reynes J, Peeters M, Segarra C, Delaporte E, and Segondy M: Effect of HIV-1 genetic diversity on HIV-1 RNA quantification in plasma: Comparative evaluations of three commercial assays. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:174.
31. Dunne AL and Drowe SM: Comparison of branched DNA and reverse transcriptase polymerase chain reaction for quantifying six different HIV-1 subtypes in plasma. AIDS 1997;11:126-127.
32. Nolte FS, Boysza J, Thurmond C, Clark WS, and Lennox JL: Clinical comparison of an enhanced-sensitivity branched DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA plasma. J Clin Microbiol 1998;36: 716-720.
33. Ou C-Y, Takebe Y, Weninger BG, Luo C-C, Kalish ML, Auwanit W, Yamazaki S, Gayle HD, Young NL, and Schochetman G: Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;341:1171-1174.
34. Pau C-P, Thomas SL, Auwanit W, George JR, Ou C-Y, Parekh BS, Granade TC, Holloman DL, Phillips S, Schochetman G, Young NL, Takebe Y, Gayle HD, and Weninger BG: Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993;7:3337-3340.
35. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, Cort S, and Sullivan JL: Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336: 1343-1349.
36. Zazzi M, Catucci M, De Milito A, Romano L, Venturi G, Almi P, Gonnelli A, Rubino M, and Valensin PE: Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment. Infection 1996;24:419-425.
37. Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, and Wain-Hobson S (eds.): Human Retroviruses and AIDS. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1997, pp. 113-115.
38. Barin F, Courouce A-M, Pillonel J, and Buzelay L: Increasing diversity of HIV-1 M serotypes in French blood donors over a 10-year period (1985-95). AIDS 1997;11:1503-1508.
39. Dietrich U, Ruppach H, Gehring S, Knechten H, Knickmann M, Jager H, Wolf E, Husak R, Orfanos CE, Brede HD, Rübsamen-Waigmann H, and von Briesen H: Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconverters. AIDS 1997;11:1532-1533.
40. Sonnerborg A, Durdevic S, Giesecke J, and Salleberg M: Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS Res Hum Retroviruses 1997;13:343-346.
41. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Fultz PN, Decker J, Girard M, Shaw GM, Hahn BH, and Sharp PM: The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70:7013-7029.